Elizabeth Plimack and Axel Merseburger highlight interesting trials within the topic of urothelial carcinoma presented at the 2021 ASCO Annual Meeting. This video is supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany.

Fredrik Liedberg and Thomas Powles discuss their thoughts on the game-changing results on metastatic urothelial carcinoma presented at ASCO GU (15:35). This activity is supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany.

An update was presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, after a median 33.7 months of follow-up.

medwireNews : ASCO has released updates to its guidelines for systemic therapy and the management of brain metastases in advanced HER2-positive breast cancer as well as for the use of biomarkers to guide systemic therapy in metastatic breast cancer.

medwireNews : ASCO has updated its recommendations for using biomarker assays to guide adjuvant therapy decisions in people with early-stage breast cancer.

ASCO GU 2022 video: Simon Crabb outlines the results of the rucaparib arm of the ATLANTIS trial of maintenance therapy in patients with metastatic

“The ASCO Expert Panel and guidelines staff will work with cochairs to keep abreast of any substantive updates to the guideline,” say the authors. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group J Clin Oncol 2021; doi:10.1200/JCO.21.02528

medwireNews : ASCO has released updated guidelines for the management of immune-related adverse events (irAEs) in people with cancer receiving immune checkpoint inhibitors (ICIs).

ASCO 2021 video: Stephen Liu talks through the latest findings from the ARROW trial of pralsetinib for patients with RET fusion-positive advanced

Gilberto Lopes shares his lung cancer highlights from the 2021 ASCO Annual Meeting, including the IMpower010 trial, the MYLUNG study of real-world molecular testing, and updates on the CodeBreaK 100 and CHRYSALIS studies.

Matteo Lambertini comments on the early and advanced breast cancer trials that caught his attention at the 2021 ASCO Annual Meeting, including the OlympiA, ECOG-ACRIN EA1131, GeparNUEVO, DAWNA-1, and sysucc-002 studies.

Preliminary research presented at the 2021 ASCO Annual Meeting suggests that use of a bacterial product might improve response to checkpoint inhibitor therapy in patients with metastatic renal cell carcinoma.

Editorial board member Axel Merseburger discusses the clinical implications of key genitourinary cancer abstracts presented at the 2021 ASCO Annual Meeting, including the KEYNOTE-564 and VISION trials, as well as brain metastases data from CheckMate 920 and updates on several enfortumab vedotin studies.

Adding the PD-L1 inhibitor durvalumab to neoadjuvant chemotherapy may improve survival outcomes in people with triple-negative breast cancer, show GeparNUEVO data presented at the 2021 ASCO Annual Meeting.

Progression-free survival for patients with metastatic urothelial carcinoma is not extended by the addition of berzosertib to cisplatin–gemcitabine chemotherapy, indicates research presented at the 2021 ASCO Annual Meeting.

Adding nivolumab to neoadjuvant chemotherapy for resectable non-small-cell lung cancer is not associated with surgical delays or complications, show CheckMate 816 data presented at the 2021 ASCO Annual Meeting.

Regular prostate cancer screening in young African–American men significantly reduces the likelihood of metastatic disease at the time of diagnosis, show study findings reported at the 2021 ASCO Annual Meeting.

Eze and co-authors continue: “Future trial designs should aim to clarify a potential effect of metformin on the characteristics of lymphocyte populations, including proliferation, cytotoxicity, and tumor infiltration.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group JAMA Oncol 2021; doi:10.1001/jamaoncol.2021.2318 JAMA Oncol 2021; doi:10.1001/jamaoncol.2021.2328 JAMA Oncol 2021; doi:10.1001/jamaoncol.2021.2316

However, please refer to your own professional and governmental guidelines for the latest guidance in your own country. 2021 ASCO Annual Meeting; 4–8 June (Abstract 12000) 2021 ASCO Annual Meeting; 4–8 June (Abstract 1503) JCO Oncol Pract 2021; doi:10.1200/OP.21.00307 2021 ASCO Annual Meeting; 4–8 June (Abstract 1504) JCO Oncol Pract 2021; doi:10.1200/OP.21.00269